The results of unrelated donor transplantation (URD-BMT) are difficult to analyze since the continuous advances in HLA typing technology allow the detection of new mismatches unknown at the time of transplantation. We sought to confirm that matched recipientdonor pairs are in fact often mismatched when advanced HLA typing techniques are used. We retrospectively studied the impact of the results of high resolution HLA typing for HLA class I (-A, -B, -C) and HLA class II (-DR, -DQ, -DP) loci, and cytotoxic T lymphocyte precursor (CTLp) frequency, on the outcome of 69 URD-BMT procedures. At the time of transplant, six (6/69) and two (2/69) donor-recipient pairs were mismatched for HLA classI (-A and -B by serology) and HLA class II, respectively, while one pair was mismatched for both HLA class I and II. Using high resolution DNA typing, HLA class I mismatches were found in 31 (45%) pairs and HLA class II mismatches in nine (13%) pairs. Twenty-three of the 69 pairs were HLA-C mismatched. Low CTLp frequencies were found among the 19 HLA class I matched pairs tested, and also in 5/14 mismatched pairs (of whom three had severe aGVHD). The overall survival of the cohort was 28 ± 6%. Among the 33 patients who were fully matched with their donors, the survival rate was 66% in the 18 patients with a standard hematological risk and 9% in the 15 high risk patients. Only two of the 33 patients developed severe aGVHD, and only one had graft rejection. Among the 36 mismatched pairs, the survival rate was 31% in the 13 patients with a standard hematological risk and 8% in the 23 high risk patients. Sixteen of these 36 patients died from severe aGVHD and four had graft failure or rejection. Three of the 10 patients with only an HLA-C mismatch died from severe aGVHD, and two had graft rejection. In conclusion: (1) donorrecipient matching based on high resolution HLA class I and II DNA typing is associated with significantly better outcome after URD-BMT; (2) the results of URD-BMT with classical GVHD prevention are comparable to Compared with genotypically HLA-identical bone marrow transplantation (BMT), grafting with an unrelated donor (URD) is associated with a higher mortality rate. Severe acute graft-versus-host disease (aGVHD) and graft failure are the main causes of transplant-related mortality (TRM) in this setting, and might be related to the degree of HLA incompatibility.
Compared with genotypically HLA-identical bone marrow transplantation (BMT), grafting with an unrelated donor (URD) is associated with a higher mortality rate. Severe acute graft-versus-host disease (aGVHD) and graft failure are the main causes of transplant-related mortality (TRM) in this setting, and might be related to the degree of HLA incompatibility. [1] [2] [3] [4] Previous standards for HLA typing have included serological methods for HLA-A and -B molecules and DNAbased typing for HLA-DRB1. HLA-DRB1 donor-recipient identity reduces the risk of aGVHD and improves survival after URD-BMT. [5] [6] [7] [8] However, the risk of aGVHD, graft failure and death remain higher among patients transplanted with HLA-A, -B and -DRB1 matched URD than among those transplanted with HLA-identical siblings. 1 Recent studies have suggested that these complications may be the result of HLA-A and -B disparities between the patient and donor. [8] [9] [10] [11] [12] Indeed, more than 300 alleles have been described at the molecular level among 85 serologically defined class I antigens. 13 Moreover, serologically HLA-A and -B 'matched' pairs are actually often HLA-C mismatched. [14] [15] [16] However, the clinical consequences of such mismatches seem unclear. In Petersdorf et al's study, 10 the HLA class I mismatches correlated more with graft failure than with acute GVHD and affected survival only in cases with multiple mismatches. On the contrary, in Sasazuki et al's study, 9 even a single HLA-A or B mismatch influenced survival rate through an increase in severe acute GVHD. In this study, locus C mismatch was associated with decreased relapse rate, and the influence of class I mismatch on the clinical outcome appeared even more important than class II mismatch.
In addition to molecular typing, cellular tests have been developed to predict the impact of HLA class I disparities on the likelihood of aGVHD. They consist of determining the frequency of donor T cell cytotoxic precursors (CTLp) with anti-recipient specificity (GVHD direction). 17 Low CTLp frequencies correlate strongly with HLA-A and -B matching. 8, 11 Since the use of URD-BMT has increased with the increased size of donor registries, more data on this topic are urgently needed to improve clinical practice, and retrospective assessment of previous experiences remain necessary for each BMT clinical team. The aim of this study was to determine the impact of HLA class I and II disparities on patient outcome after URD-BMT. We retyped HLA class I and II, using high resolution DNA techniques, in the 69 donor-recipient pairs transplanted between September 1988 and June 1998 in our institution. CTLp frequencies were also determined in 33 of these pairs.
Materials and methods

BMT procedure
The 69 consecutive URD-BMT procedures performed between September 1988 and June 1998 at Henri-Mondor University Hospital were included in the study (Table 1) . Three patients were grafted twice. Donors were identified through the European and NMDP registries. The main pre-BMT characteristics of the patients are summarized in Table 1 . Patients were divided into two groups according to disease status at BMT: the 32 recipients with CML in first chronic phase or acute leukemia in first or second remission formed the standard risk group, and the 37 patients with more advanced disease at BMT formed the high risk group. The 66 first BMT procedures were performed after myeloablative conditioning including total body irradiation (n = 59) or a busulfan-based regimen (n = 7). The three second grafts using a different donor, were done after procarbazine-cyclophosphamide and antithymocyte globulin. GVHD prophylaxis combined cyclosporine and methotrexate according to the Seattle protocol. 18 All patients received unmodifed bone marrow. Acute GVHD was classified as defined by Glucksberg et al. 19 and was treated with standard doses of steroids followed, in the event of failure, by high-dose steroids or ATG.
HLA typing and patient-donor matching
Pre-BMT HLA typing: Donors were selected on the basis of HLA-A and -B typing by the microlymphocytotoxicity technique 20 identifying the relevant World Health Organization (WHO)-recognized specificities at the time of transplant. HLA class II typing was done with the techniques available at the time of tranplant. Thus, HLA-DR and -DQ phenotypes were studied at low resolution in 14 pairs by means of serology (n = 3) or RFLP (restriction fragment length polymorphism) (n = 11), while in the other 55 pairs, HLA-DRB1, -DQB1 and -DPB1 typing were performed at high resolution by means of PCR-reverse dot blot (Innogenetics, Brussels, Belgium) plus PCR-RFLP 21, 22 for HLA-DRB1 and -DQB1.
Retrospective HLA typing: HLA class I typing was done retrospectively by means of PCR-SSP (sequence-specific primer) (Dynal, Oslo, Norway).
HLA-A and HLA-B serological 'blanks' were re-typed by using low resolution DNA typing. All serologically expressed HLA-A antigens were defined at the allelic level. Serologically expressed HLA-B antigens were defined at high resolution according to the availability of commercial kits (the HLA-B phenotype was entirely defined at high resolution in 39 of the 69 donor-recipient pairs). The HLA-C locus was studied by means of a technique defining the Cw1-18 alleles.
HLA-DRB1, -DQB1 and -DPB1 were retyped in the 14 donor-recipient pairs previously typed at low resolution.
Calculation of CTL-p frequencies
CTLp assays were carried out as described by Kaminski et al. 17 Briefly, assays were run in the 'GVHD direction', with donor cells used as responder cells and recipient cells as stimulator cells. Wells were scored as positive if their 51 Cr release was greater than the mean plus 3 standard deviations (s.d.) of the negative control (stimulator cells without responder cells). CTLp frequencies below 1/300 000 were considered negative.
Statistical methods
Data were collected and updated as of 15 November 1998, providing a minimum patient follow-up of 7 months, a maximum of 122 months, and a median survivor followup of 29 months (range 7-122 months). The estimated probabilities of aGVHD, TRM and survival were calculated and plotted with the Kaplan-Meier method and compared using the log-rank test. Patients who underwent second transplants were censored for the first transplant at the date of the second BMT.
Results
HLA typing and pCTL frequencies
At the time of transplantation, six donor-recipient pairs were known to be mismatched for one HLA-A or -B antigen (UPN 671, 588, 536, 620, 629, 643); two pairs were HLA-DQB1 mismatched (UPN 495, 547) and one pair was HLA-A and -DQB mismatched (UPN 502) ( Table 2) .
Retrospective DNA typing confirmed all the serologically identified mismatches. Additional mismatches were found in seven of the nine known mismatched donorrecipient pairs (Table 2) . Among the 60 other donor-recipient pairs, HLA incompatibilities not identified at the time of transplant were detected in 27/60 (45%), while 33/60 (55%) pairs were confirmed as being matched for HLA-A, -B, -C, -DRB1 and -DQB1 alleles. Thus, after retrospective typing, a total of 36/69 (52%) donor-recipient pairs were mismatched. Among these pairs, 27 were only mismatched for HLA class I antigens, five pairs were only mismatched for HLA class II antigens, and four were mismatched for both HLA class I and class II antigens.
HLA class I
Serologically blank phenotypes were always confirmed by low resolution DNA typing, which also showed that one individual had been mis-identified by serological typing (HLA-B57(17) instead of HLA-B58(17) (UPN 502)). Among the 62 pairs who were serologically HLA-A and -B matched at the time of transplant, HLA-A and/or -B mismatches were detected in 13 after retrospective typing (Tables 2 and 3 ). HLA-B antigens were determined by high resolution typing in 17/33 matched donor-recipient pairs and 22/36 mismatched pairs.
Among the 69 pairs, 23 were HLA-C mismatched (Table  3) . Ten had only one HLA-C antigen mismatch, while 12 also had HLA-A and/or -B mismatches and one also had one HLA class II mismatch (Tables 2 and 4 ). All HLA-B molecules were typed at high resolution in the 10 pairs with only HLA-C mismatches. Thus, after retrospective DNA typing, 31/69 (45%) pairs had at least one HLA class I mismatch.
HLA class II
Among the 14 donor-recipient pairs who were phenotyped at low resolution at the time of transplant, mismatches were Bone Marrow Transplantation discovered by retrospective typing in six supposedly HLA class II-identical donor-recipient pairs; of these, three were HLA-DQB1 mismatched (UPN 392, 441, 380), one was HLA-DRB1 and -DQB1 mismatched (UPN 373) and two were HLA class I and class II mismatched (UPN 426, 306) ( Table 2) . Thus, 9/69 donor-recipient pairs were HLA class II mismatched.
HLA-DPB1 typing showed that only nine patient-donor pairs were matched in this respect. In total, only five pairs were HLA-A, -B, -C, -DRB1, -DQB1 and -DPB1 identical.
Ancestral haplotypes
To determine if the mismatch frequency found by high resolution DNA typing could be predicted on the basis of conserved haplotypes, we classified the donor-recipient pairs' HLA phenotypes identified at the time of transplantation, on the basis of the probable presence of one or two of the 25 ancestral HLA-ABDR haplotypes (AH) defined by Christiansen et al. 23 The presence of AH could not be analyzed in eight donor-recipient pairs (seven with known HLA mismatches at the time of transplantation and one with multiple mismatches preventing haplotype reconstitution). Two pairs might have two AH, 29 one AH, and 30 no AH. Among the 122 haplotypes analyzed, HLA class I mismatches were more frequent after high resolution DNA typing within the haplotypes considered non-ancestral than within the AH (21/89 vs 2/33) (P = 0.017 Fisher's exact test).
CTLp
CTLp frequencies were determined for 33 pairs. After DNA typing, 14 pairs were HLA class I mismatched in the GVHD direction and 19 pairs were matched (Table 5) . Among the 14 mismatched pairs, a high frequency of CTLp was found in nine pairs and low frequencies in five pairs. Of these latter five pairs, two were HLA-A mismatched (UPN 671, 547), one was HLA-B mismatched (UPN 642) and two were HLA-C mismatched (UPN 680, 668). Low CTLp frequencies were found in the 19 pairs matched in the GVHD direction.
Engraftment
Six patients died before day 30 after transplantation, meaning that 63 grafts could be evaluated. Graft failure occurred in five cases. Four of the five pairs were HLA class I mismatched in the HVG (host-versus-graft) direction (UPN 526, 436, 617, 536) and one was matched. Two patients had one HLA-C antigen mismatch (UPN 617, 436), one had one HLA-B antigen mismatch (UPN 526), and one had HLA-B and -C mismatches (UPN 536).
AGVHD, TRM and survival
Nineteen out of 66 patients are alive (median 28 months, range 7-122 months after BMT), including a patient with autologous reconstitution (UPN 617) and a patient in relapse from lymphoma (UPN 600). The overall survival rate for the entire cohort is 28 ± 6%, and values correlated with hematologic status (55% vs 9%) (P Ͻ 0.01) (Figure Table 2 Details of the HLA typing in the 36 mismatched pairs Table 3 Frequency of HLA matching before and after retrospective DNA typing 1). Survival also correlated with HLA matching: overall survival was 40% in the matched group and only 20% in the mismatched group ( Figure 2 ) (P Ͻ 0.05). TRM was significantly higher in the mismatched group (85%) than in the matched group (40%) (P Ͻ 0.01). Among the 63 assessable patients, severe (grade III-IV) aGVHD was observed in 18 cases (28.5%): 2/30 patients (7%) in the matched group had severe aGVHD, compared to 16/33 (48%) of those in the mismatched group (P Ͻ 0.05) (Figure 3) . Among the five patients with negative CTLp despite HLA class I mismatching, three had severe aGVHD (UPN 547, 671, 680) and two did not. Among the 60 HLA class II-matched pairs, the survival rate was 42% among the 33 patients transplanted with an HLA-A, -B, -C, -DRB1 and -DQB1 identical unrelated donor, compared to 18% among the 27 patients with an HLA class I-mismatched graft (P Ͻ 0.05) (Figure 4) . TRM Bone Marrow Transplantation Table 5 HLA was 40% and 92%, respectively, in the two groups (P Ͻ 0.01). Among the 10 patients transplanted with only HLA-C mismatched grafts, four died from aGVHD and two had graft rejection (Table 6) .
Of the five patients fully matched for HLA-A, -B, -C, -DRB1, -DQB1 and -DPB1, one survived and four died (one from severe aGVHD).
Finally, when survival was analyzed according to matching and hematologic status, overall survival in the standard risk group was 66% among matched patients and 31% among mismatched patients (P Ͻ 0.05) ( Figure 5 ).
Discussion
Our study clearly confirms that survival after URD-BMT could be improved by matching donor and recipient for HLA-A, -B, -C at a high resolution level, indicating that HLA incompatibilities only detected by high resolution typing (ie missed by conventional techniques) are clinically relevant. Although this has been known for HLA class II matching for several years, it has only been established for HLA class I by two recent studies.
9,10 Our study shows the high frequency of HLA class I mismatching among the HLA-A and -B serologically identical donor-recipient pairs. Indeed, allelic HLA-A and/or -B mismatches were discovered in 13/62 (21%) serologically matched pairs, and in 6/7 (86%) pairs known to be mismatched at the time of transplantation. Moreover, this study underlines the high frequency of HLA-C mismatching (23/69, 33%), which occurred in 11/23 of cases without HLA-A and/or -B mismatching.
Interestingly, our analysis suggests that AH are less frequently associated with allelic HLA class I disparities, in agreement with Prasad et al's study. 12 However, it should be noted that AH segregation is based on a probability calculation, and could not be determined by donor family studies.
Recently, CTLp tests were introduced by many transplantation units, with the aim of detecting missed HLA class I mismatches, or predicting aGVHD. 8 In our center, CTLp results were used for donor selection before transplantation, and the donors with the highest CTLp tests were eliminated. In this study, when CTLp and DNA typing were compared, high CTLp tests were always associated with HLA class I mismatches. However, negative CTLp tests were observed in five pairs despite a mismatch in the GVHD direction (including three cases with HLA-A or -B mismatch) which is in agreement with Scott et al's study. 11 CTLp might be useful for detecting permissive HLA class I mismatches. However, the occurrence of severe aGVHD in two of the four patients with only HLA class I mismatches and negative CTLp tests prevents us from confirming this possibility.
Recently, two studies showed the correlation between HLA class I matching and clinical outcome. 9, 10 Sasazuki et al 9 found a correlation between HLA-A, -B and -C mismatching and a high incidence of severe aGVHD, while class I mismatching was associated with graft rejection in 43 Petersdorf et al's study, 10 especially for the HLA-C locus. 24 On the other hand, Sasazuki et al found that HLA-C matching correlated with the risk of leukemia relapse, 21 which may be explained by the inhibition of NK cell activity in cases of HLA-C identity between donor and recipient. 25, 26 The divergent results between the two studies may be explained by differences in ethnic background and hematological disease (CML patients vs national registry). In our study, the high tranplant-related mortality observed within the HLA class I mismatched patients was due to a high incidence of severe aGVHD. Moreover, 4/5 cases of graft failure were also observed in this group of patients. Thus, HLA-C mismatching might be associated with both severe aGVHD and graft failure, confirming the role of HLA-C as a transplantation antigen. The influence of HLA-C identity on leukemia relapse could not be analyzed in our work, given the low number of donor-recipient pairs.
In conclusion, genomic typing of HLA class I and II alleles adds considerably to the success of transplantation from unrelated donors, with a median survival in the matched group comparable to the survival in geno-identical sibling transplantation. The poor prognosis of patients who undergo HLA mismatched transplantation suggests the need for new transplantation modalities.
